aTyr Pharma Inc reports results for the quarter ended June 30 - Earnings Summary

• aTyr Pharma Inc ATYR.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -23 cents. The mean expectation of ten analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -25 cents to -17 cents per share.

• Reported revenue was zero​; analysts expected zero.

• aTyr Pharma Inc's reported EPS for the quarter was a loss of 22 cents​.

• The company reported a quarterly loss of $19.53 million.

• aTyr Pharma Inc shares had risen by 4.5% this quarter and gained 46.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for aTyr Pharma Inc is $18.00, about 70.6% above its last closing price of $5.30

This summary was machine generated from LSEG data August 11 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)